Navigating New Complexities in “Standard” Multiple Myeloma Management
The landscape of “standard” care in multiple myeloma is rapidly evolving as new therapeutic classes emerge, and data continues to refine how clinicians define risk, assess response and sequence treatments. Advances in therapies, evolving definitions of high-risk cytogenetics and the growing role of minimal residual disease (MRD) monitoring are reshaping clinical decision-making across the disease continuum.
These emerging advancements often outpace formal guideline updates, requiring clinicians to make complex, individualized decisions based on trial results, evolving standards, and patient preferences—with little consensus on best practices.
“Tailoring the design [of treatment options] for patients is critical because we all play a role in optimal health outcomes. Patient and provider understanding and empowerment is essential to ensuring early intervention and optimized care for MM patients.”
– Monique Hartley-Brown, MD, MMSc,
Attending Physician, Jerome Lipper Multiple Myeloma Center,
Department of Medical Oncology, Dana-Farber Cancer Institute
This is why Medlive focuses on real-world readiness. Our scenario-based tracks, peer insight polling, and real-life patient case reviews don’t just teach the ‘what.’ They equip oncologists with the ‘now what’—the critical context that empowers clinicians to act with precision, even when the path forward isn’t fully defined.
“We track how HCPs interact with content—not just if they viewed it, but how they moved through it—and we adapt learning opportunities based on that.”
— Tariqa Ackbarali, PhD, MS, CHCP
Vice President, Medical Oncology, Medlive
If you’re heading to ASCO, come to booth #34070 to see how we’re building education that moves as fast as the science—or check out our latest real-world case discussions, emerging data updates, and peer insights at www.medlive.com/cancer anytime.
